Skip to main content
. 2018 Feb 21;15:53. doi: 10.1186/s12974-018-1093-9

Fig. 4.

Fig. 4

Nrg-1 treatment promotes Breg cell population following SCI. a Representative images of the gating strategy for flow cytometry of spinal cord are provided. b At 7 days post-injury, the number of CD45RA+ B cells was significantly increased in the spinal cord without any significant difference in the total and regulatory B cell populations between vehicle- and Nrg-1-treated groups. c At 14-day post-SCI, a significant increase in the number of Breg cells was observed in Nrg-1-treated animals compared to vehicle-treated group. d Chronically at 42 days post-SCI, the number of B cells in the spinal cord reached the highest level compared to all earlier time-points. Nrg-1 treatment resulted in a significant increase in the number of infiltrated B cells in the spinal cord and promoted IL-10 expressing Breg cells compared to vehicle treatment. e Immunohistochemical analysis verified the presence of Breg cells in the perilesional area of the injured spinal cord. f Representative images of the gating strategy for flow cytometry of blood are provided. g Analysis of the blood revealed a significant decline in B cell population at 7 days post-SCI without any significant change in the Breg cell population at this time-point. h, i No significant change in total and regulatory B cell populations were observed in the blood at 14- and 42-day time-points. (N = 5/group/time-point, *p < 0.05, **p < 0.01, ***p < 0.001, one-way ANOVA followed by Holm-Sidak post hoc test)